Esophagitis medical therapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(21 intermediate revisions by 6 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Esophagitis}}
{{Esophagitis}}
{{CMG}}
{{CMG}} {{AE}} {{Ajay}}


==Overview==
==Overview==
Treatment of esophagitis should be directed against the specific etiology.  The mainstay of therapy for reflux esophagitis includes pharmacologic agents that block gastric acid productionAntimicrobial therapy is indicated in infectious esophagitis. Certain lifestyle changes may help to reduce symptoms.
 
The mainstay of therapy for reflux esophagitis is acid suppression therapyPatients with infectious esophagitis are treated with [[antimicrobial]] therapy, whereas patients with eosinophilic esophagitis are treated with [[corticosteroids]]. Supportive therapy for esophagitis includes [[proton pump inhibitors]], topical pain medications (gargled or swallowed), smoking and alcohol cessation, and [[endoscopy]] to remove any lodged pill fragments.


==Medical Therapy==
==Medical Therapy==
Treatment of esophagitis depends on the underlying cause:
Treatment of esophagitis depends on the underlying cause along with dietary modifications
*''[[Reflux esophagitis]]'': Acid suppression using proton-pump inhibitors
=== '''Dietary Modification''' ===
*''[[Infectious esophagitis]]'': Antibiotics, antifungals, or antivirals depending on organism (see regimens below)
* '''Elemental diet-''' highly effective in both adults and children, but it is limited by patient tolerability.  
*''[[Eosinophilic esophagitis]]'': Topical/systemic corticosteroids<ref name="pmid19596009">{{cite journal| author=Rothenberg ME| title=Biology and treatment of eosinophilic esophagitis. | journal=Gastroenterology | year= 2009 | volume= 137 | issue= 4 | pages= 1238-49 | pmid=19596009 | doi=10.1053/j.gastro.2009.07.007 | pmc=PMC4104422 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19596009  }} </ref>
* '''Empiric six-food elimination diet (SFED)-'''  the most common foods that trigger EoE are: soy, fish, cow milk, nuts, eggs, wheat.  
*''[[Pill-induced esophagitis]]'': Stop offending drug<ref name="pmid19392845">{{cite journal| author=Zografos GN, Georgiadou D, Thomas D, Kaltsas G, Digalakis M| title=Drug-induced esophagitis. | journal=Dis Esophagus | year= 2009 | volume= 22 | issue= 8 | pages= 633-7 | pmid=19392845 | doi=10.1111/j.1442-2050.2009.00972.x | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19392845  }} </ref>
* '''Limited diet driven by allergy testing and patient history-''' The allergy testing directs diet approach, although effective in the [[Pediatrics|pediatric]] group has only moderate success in adults.
*''[[Radiation esophagitis]]'': Sucralfate, promotility agents, and viscous lidocaine<ref name="pmid20704169">{{cite journal| author=Berkey FJ| title=Managing the adverse effects of radiation therapy. | journal=Am Fam Physician | year= 2010 | volume= 82 | issue= 4 | pages= 381-8, 394 | pmid=20704169 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20704169  }} </ref>
* The goal of [[dietary]] therapy is identification and removal of [[food]] [[antigens]] and consequently remove the [[sensitization]].  
 
* Diet therapy gives patients an alternative to control their disease, many patients find the idea of managing their sickness by means of removing the [[Nutrition|nutritional]] trigger moe appealing than taking a drug to counteract the downstream [[inflammatory]] response. 
Supportive care measures include:
* It is far vital to emphasize that the stern dietary elimination of multiple foods is only for a limited time but the long-term goal is the identify and  remove the triggering dietary elements.
*Acid suppression using proton-pump inhibitors (recommended in all patients)
* Prolonged deviation from the elimination diet can be managed via intermittent use of quick courses of [[topical]] [[steroids]].
*Topical pain medications (gargled or swallowed)
*Decreasing or limiting oral intake, total parenteral nutrition (TPN) may be required for advanced cases to allow the esophagus to heal
*Smoking/Alcohol cessation
*Endoscopy to remove any lodged pill fragments
 
===Antimicrobial Regimens===


*'''1. Candida esophagitis'''<ref>{{cite book | last = Bennett | first = John | title = Mandell, Douglas, and Bennett's principles and practice of infectious diseases | publisher = Elsevier/Saunders | location = Philadelphia, PA | year = 2015 | isbn = 978-1455748013 }}</ref>
== Medical therapy ==
:*Preferred regimen: [[Fluconazole]] 100 mg PO qd for 14–21 days {{or}} [[Itraconazole]] solution 200 mg PO qd for 14–21 days
The medical therapy is indicated for the patients who have persistent GERD regardless the lifystyle and food modifications. The following medical therapies are strongly recommended by the American College of Gastroenterology:<ref>Decktor DL, Robinson M, Maton PN, Lanza FL, Gottlieb S. Effects of Aluminum/Magnesium Hydroxide and Calcium Carbonate on Esophageal and Gastric pH in Subjects with Heartburn. ''Am J Ther'' 1995;2:546-552. PMID 11854825.</ref><ref name="pmid17229239">{{cite journal |author=Tran T, Lowry A, El-Serag H |title=Meta-analysis: the efficacy of over-the-counter gastro-oesophageal reflux disease drugs |journal=Aliment Pharmacol Ther |volume=25 |issue=2 |pages=143-53 |year=2007 |id=PMID 17229239 | doi=10.1111/j.1365-2036.2006.03135.x}}</ref>.<ref>{{Cite journal| doi = 10.1038/ajg.2013.71| issn = 1572-0241| volume = 108| issue = 5| pages = 679–692; quiz 693| last1 = Dellon| first1 = Evan S.| last2 = Gonsalves| first2 = Nirmala| last3 = Hirano| first3 = Ikuo| last4 = Furuta| first4 = Glenn T.| last5 = Liacouras| first5 = Chris A.| last6 = Katzka| first6 = David A.| last7 = American College of Gastroenterology| title = ACG clinical guideline: Evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE)| journal = The American Journal of Gastroenterology| date = 2013-05| pmid = 23567357}}</ref>
:*Alternative regimen (1): [[Itraconazole]] tablets 200 mg PO qd for 14–21 days
* '''Reflux esophagitis'''
:*Alternative regimen (2): [[Amphotericin B]] 0.3–0.7 mg/kg/d IV q24h
** '''[[Antacids]]''':
:*Amphotericin B is reserved for patients who have failed therapy with both fluconazole and itraconazole.
*** Preferred regimen (1): [[Aluminum hydroxide]] 640 mg 5 to 6 times daily PO after meals and at bed time.
*** Preferred regimen (2): [[Calcium carbonate]] One gram PO.
** '''Histamine-receptor antagonists (H2RA):'''
*** Preferred regimen (1): [[Ranitidine]] 150 mg q12 daily PO
*** Preferred regimen (2): [[Cimetidine]] 400 mg q6h or 800 mg q12 PO for 12 weeks
*** Preferred regimen (3): [[Famotidine]] 20 mg q12 PO for 6 weeks
** '''[[Proton pump inhibitors]]:'''
*** Preferred regimen (1): [[Omeprazole]] 20 mg q24 PO for up to 4 weeks
*** Preferred regimen (2): [[Esomeprazole]] 20 mg or 40 mg q24 IV  
** '''[[Prokinetic|Prokinetic medications]]:'''
*** Preferred regimen (1): [[Metoclopramide]] 10 mg q24 PO for 4 to 12 weeks


*'''2. Herpes simplex virus (HSV) esophagitis'''<ref>{{cite book | last = Bennett | first = John | title = Mandell, Douglas, and Bennett's principles and practice of infectious diseases | publisher = Elsevier/Saunders | location = Philadelphia, PA | year = 2015 | isbn = 978-1455748013 }}</ref>
*'''Infectious esophagitis'''
:*Preferred regimen (1): [[Acyclovir]] 5 mg/kg IV q8h for 7–14 days  
**'''1. Candida esophagitis'''<ref>{{cite book | last = Bennett | first = John | title = Mandell, Douglas, and Bennett's principles and practice of infectious diseases | publisher = Elsevier/Saunders | location = Philadelphia, PA | year = 2015 | isbn = 978-1455748013 }}</ref>
:*Preferred regimen (2): [[Acyclovir]] 400 mg 5 times daily PO for 14–21 days
***Preferred regimen: [[Fluconazole]] 100 mg PO qd for 14–21 days {{or}} [[Itraconazole]] solution 200 mg PO qd for 14–21 days
:*Preferred regimen (3): [[Valacyclovir]] 1 g PO tid for 14–21 days {{withorwithout}} maintenance suppressive therapy may be necessary in AIDS
***Alternative regimen (1): [[Itraconazole]] tablets 200 mg PO qd for 14–21 days
:*Alternative regimen (1): [[Famciclovir]] 500 mg bid PO for 14–21 days  
***Alternative regimen (2): [[Amphotericin B]] 0.3–0.7 mg/kg/d IV q24h
:*Alternative regimen (2): [[Foscarnet]] 90 mg/kg q12h IV for 7–14 days
***Amphotericin B is reserved for patients who have failed therapy with both fluconazole and itraconazole.
**'''2. Herpes simplex virus (HSV) esophagitis'''<ref>{{cite book | last = Bennett | first = John | title = Mandell, Douglas, and Bennett's principles and practice of infectious diseases | publisher = Elsevier/Saunders | location = Philadelphia, PA | year = 2015 | isbn = 978-1455748013 }}</ref>
***Preferred regimen (1): [[Acyclovir]] 5 mg/kg IV q8h for 7–14 days  
***Preferred regimen (2): [[Acyclovir]] 400 mg 5 times daily PO for 14–21 days
***Preferred regimen (3): [[Valacyclovir]] 1 g PO tid for 14–21 days {{withorwithout}} maintenance suppressive therapy may be necessary in AIDS
***Alternative regimen (1): [[Famciclovir]] 500 mg bid PO for 14–21 days  
***Alternative regimen (2): [[Foscarnet]] 90 mg/kg q12h IV for 7–14 days
**'''3. Cytomegalovirus (CMV) esophagitis'''<ref>{{cite book | last = Bennett | first = John | title = Mandell, Douglas, and Bennett's principles and practice of infectious diseases | publisher = Elsevier/Saunders | location = Philadelphia, PA | year = 2015 | isbn = 978-1455748013 }}</ref>
***Preferred Regimen (1): Ganciclovir 5 mg/kg IV q12h, may switch to valganciclovir 900 mg PO q12h once the patient can absorb and tolerate PO therapy.
***Alternate Regimen (1): Foscarnet 60 mg/kg IV q8h or 90 mg/kg IV q12h for patients with treatment limiting toxicities to ganciclovir or with ganciclovir resistance {{or}}
***Alternate Regimen (2): Oral valganciclovir may be used if symptoms are not severe enough to interfere with oral absorption {{or}}
***Alternate Regimen (3):  For mild cases: If ART can be initiated or optimized without delay, withholding CMV therapy may be considered.
****Note (1): Maintenance therapy is usually not necessary, but should be considered after relapses.


*'''3. Cytomegalovirus (CMV) esophagitis'''<ref>{{cite book | last = Bennett | first = John | title = Mandell, Douglas, and Bennett's principles and practice of infectious diseases | publisher = Elsevier/Saunders | location = Philadelphia, PA | year = 2015 | isbn = 978-1455748013 }}</ref>
*[[Eosinophilic esophagitis|'''Eosinophilic esophagitis''']]
:*Preferred regimen: [[Ganciclovir]] 5 mg/kg IV q12h for 14–21 days
**'''Steroid Therapy'''
:*Alternative regimen (1): [[Foscarnet]] 90 mg/kg IV q12h for 14–21 days, then [[Foscarnet]] 90–120 mg/kg/day IV for maintenance in AIDS patients
***Preferred regimen (1) : [[fluticasone]] 880–1760 mcg PO qd
:*Alternative regimen (2): [[Valganciclovir]] 900 mg PO bid, then 900 mg PO qd for maintenance in AIDS patients
***Preferred regimen (2) : [[Budesonide]] 1 mg PO qd for children, 2 mg PO qd
:*Note: Maintenance therapy with [[Ganciclovir]] 5 mg/kg/day IV or 6 mg/kg/day IV 5 days per week in AIDS patients.
 
==Eosinophilic Esophagitis==
{{Main|Eosinophilic esophagitis medical therapy}}
 
The optimal treatment of [[eosinophilic esophagitis]] remains uncertain.  The endpoints of therapy of [[eosinophilic esophagitis]] include improvements in clinical symptoms and esophageal [[eosinophilic]] [[inflammation]].  An eight-week course of therapy with topical corticosteroids ('''[[fluticasone]]''' 88–440 mcg/day for children or 880–1760 mcg/day for adults or '''[[budesonide]]''' 1 mg/day for children or 2 mg/day for adults) may be used as the first-line pharmacologic therapy.  Patients without symptomatic and histologic improvement after topical [[steroids]] may benefit from a longer course or higher doses of topical [[steroids]], systemic [[steroids]] with [[prednisone]], dietary elimination, or endoscopic dilation.<ref>{{Cite journal| doi = 10.1038/ajg.2013.71| issn = 1572-0241| volume = 108| issue = 5| pages = 679–692; quiz 693| last1 = Dellon| first1 = Evan S.| last2 = Gonsalves| first2 = Nirmala| last3 = Hirano| first3 = Ikuo| last4 = Furuta| first4 = Glenn T.| last5 = Liacouras| first5 = Chris A.| last6 = Katzka| first6 = David A.| last7 = American College of Gastroenterology| title = ACG clinical guideline: Evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE)| journal = The American Journal of Gastroenterology| date = 2013-05| pmid = 23567357}}</ref>  Evaluation by an allergist for coexisting [[atopy|atopic disorders]] and food and environmental [[allergens]] is advisable.  [[Allergen]] elimination usually leads to improvement in [[dysphagia]] and reduction of [[eosinophil]] infiltration.  Graduated dilation of [[esophageal stricture]] should be performed with caution to minimize the risk of iatrogenic [[perforation]].
 
==Contraindicated Medications==
{{MedCondContrAbs
|MedCond = Reflux esophagitis|Dicyclomine}}


==References==
==References==
Line 57: Line 64:
[[Category:Gastroenterology]]
[[Category:Gastroenterology]]
[[Category:Histopathology]]
[[Category:Histopathology]]
[[Category:Inflammations]]
 
{{WS}}
{{WH}}

Latest revision as of 17:38, 29 January 2018

Esophagitis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Esophagitis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Esophagitis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Esophagitis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Esophagitis medical therapy

CDC on Esophagitis medical therapy

Esophagitis medical therapy in the news

Blogs on Esophagitis medical therapy

Directions to Hospitals Treating Esophagitis

Risk calculators and risk factors for Esophagitis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Ajay Gade MD[2]]

Overview

The mainstay of therapy for reflux esophagitis is acid suppression therapy. Patients with infectious esophagitis are treated with antimicrobial therapy, whereas patients with eosinophilic esophagitis are treated with corticosteroids. Supportive therapy for esophagitis includes proton pump inhibitors, topical pain medications (gargled or swallowed), smoking and alcohol cessation, and endoscopy to remove any lodged pill fragments.

Medical Therapy

Treatment of esophagitis depends on the underlying cause along with dietary modifications

Dietary Modification

  • Elemental diet- highly effective in both adults and children, but it is limited by patient tolerability.
  • Empiric six-food elimination diet (SFED)- the most common foods that trigger EoE are: soy, fish, cow milk, nuts, eggs, wheat.
  • Limited diet driven by allergy testing and patient history- The allergy testing directs diet approach, although effective in the pediatric group has only moderate success in adults.
  • The goal of dietary therapy is identification and removal of food antigens and consequently remove the sensitization.
  • Diet therapy gives patients an alternative to control their disease, many patients find the idea of managing their sickness by means of removing the nutritional trigger moe appealing than taking a drug to counteract the downstream inflammatory response.
  • It is far vital to emphasize that the stern dietary elimination of multiple foods is only for a limited time but the long-term goal is the identify and remove the triggering dietary elements.
  • Prolonged deviation from the elimination diet can be managed via intermittent use of quick courses of topical steroids.

Medical therapy

The medical therapy is indicated for the patients who have persistent GERD regardless the lifystyle and food modifications. The following medical therapies are strongly recommended by the American College of Gastroenterology:[1][2].[3]

  • Infectious esophagitis
    • 1. Candida esophagitis[4]
      • Preferred regimen: Fluconazole 100 mg PO qd for 14–21 days OR Itraconazole solution 200 mg PO qd for 14–21 days
      • Alternative regimen (1): Itraconazole tablets 200 mg PO qd for 14–21 days
      • Alternative regimen (2): Amphotericin B 0.3–0.7 mg/kg/d IV q24h
      • Amphotericin B is reserved for patients who have failed therapy with both fluconazole and itraconazole.
    • 2. Herpes simplex virus (HSV) esophagitis[5]
      • Preferred regimen (1): Acyclovir 5 mg/kg IV q8h for 7–14 days
      • Preferred regimen (2): Acyclovir 400 mg 5 times daily PO for 14–21 days
      • Preferred regimen (3): Valacyclovir 1 g PO tid for 14–21 days ± maintenance suppressive therapy may be necessary in AIDS
      • Alternative regimen (1): Famciclovir 500 mg bid PO for 14–21 days
      • Alternative regimen (2): Foscarnet 90 mg/kg q12h IV for 7–14 days
    • 3. Cytomegalovirus (CMV) esophagitis[6]
      • Preferred Regimen (1): Ganciclovir 5 mg/kg IV q12h, may switch to valganciclovir 900 mg PO q12h once the patient can absorb and tolerate PO therapy.
      • Alternate Regimen (1): Foscarnet 60 mg/kg IV q8h or 90 mg/kg IV q12h for patients with treatment limiting toxicities to ganciclovir or with ganciclovir resistance OR
      • Alternate Regimen (2): Oral valganciclovir may be used if symptoms are not severe enough to interfere with oral absorption OR
      • Alternate Regimen (3): For mild cases: If ART can be initiated or optimized without delay, withholding CMV therapy may be considered.
        • Note (1): Maintenance therapy is usually not necessary, but should be considered after relapses.

References

  1. Decktor DL, Robinson M, Maton PN, Lanza FL, Gottlieb S. Effects of Aluminum/Magnesium Hydroxide and Calcium Carbonate on Esophageal and Gastric pH in Subjects with Heartburn. Am J Ther 1995;2:546-552. PMID 11854825.
  2. Tran T, Lowry A, El-Serag H (2007). "Meta-analysis: the efficacy of over-the-counter gastro-oesophageal reflux disease drugs". Aliment Pharmacol Ther. 25 (2): 143–53. doi:10.1111/j.1365-2036.2006.03135.x. PMID 17229239.
  3. Dellon, Evan S.; Gonsalves, Nirmala; Hirano, Ikuo; Furuta, Glenn T.; Liacouras, Chris A.; Katzka, David A.; American College of Gastroenterology (2013-05). "ACG clinical guideline: Evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE)". The American Journal of Gastroenterology. 108 (5): 679–692, quiz 693. doi:10.1038/ajg.2013.71. ISSN 1572-0241. PMID 23567357. Check date values in: |date= (help)
  4. Bennett, John (2015). Mandell, Douglas, and Bennett's principles and practice of infectious diseases. Philadelphia, PA: Elsevier/Saunders. ISBN 978-1455748013.
  5. Bennett, John (2015). Mandell, Douglas, and Bennett's principles and practice of infectious diseases. Philadelphia, PA: Elsevier/Saunders. ISBN 978-1455748013.
  6. Bennett, John (2015). Mandell, Douglas, and Bennett's principles and practice of infectious diseases. Philadelphia, PA: Elsevier/Saunders. ISBN 978-1455748013.

Template:WS Template:WH